截至10月20日，力生制药股东户数2.39万，较上期增加0.13%；人均流通股10479股，较上期减少 0.13%。2025年1月-9月，力生制药实现营业收入10.07亿元，同比减少1.61%；归母净利润3.71亿元，同 比增长119.05%。 分红方面，力生制药A股上市后累计派现12.61亿元。近三年，累计派现2.55亿元。 责任编辑：小浪快报 融券方面，力生制药12月19日融券偿还0.00股，融券卖出1300.00股，按当日收盘价计算，卖出金额2.69 万元；融券余量4000.00股，融券余额8.28万元，超过近一年90%分位水平，处于高位。 资料显示，天津力生制药股份有限公司位于天津市西青经济技术开发区赛达北一道16号，成立日期1981 年6月17日，上市日期2010年4月23日，公司主营业务涉及从事化学药片剂、硬胶囊剂、滴丸剂、冻干粉 针剂、水针剂、原料药等产品的生产销售。主营业务收入构成为：片剂59.92%，针剂15.69%，丸剂 8.80%，胶囊8.75%，其他4.68%，颗粒剂2.16%。 12月19日，力生制药涨1.27%，成交额5298.53万元。两融数据显示，当日力生制药获融资买入额373 ...

资料显示，哈尔滨三联药业股份有限公司位于黑龙江省哈尔滨市利民开发区北京路，成立日期1996年6 月21日，上市日期2017年9月22日，公司主营业务涉及化学药品制剂的研发、生产和销售。主营业务收 入构成为：大输液32.00%，冻干粉针剂18.39%，固体制剂17.39%，小容量注射剂14.34%，其他(补 充)10.26%，兽药2.55%，进出口贸易1.82%，原料药1.73%，化妆品0.94%，医疗器械0.43%，功能食品 0.16%。 哈三联所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：高血压防治、抗流感、肝 炎治疗、创新药、宠物经济等。 12月18日，哈三联盘中上涨2.10%，截至13:41，报13.15元/股，成交4103.33万元，换手率1.81%，总市 值41.60亿元。 资金流向方面，主力资金净流入46.33万元，大单买入354.33万元，占比8.64%，卖出308.00万元，占比 7.51%。 哈三联今年以来股价涨36.27%，近5个交易日跌1.79%，近20日跌4.29%，近60日跌4.15%。 今年以来哈三联已经9次登上龙虎榜，最近一次登上龙虎榜为6月3日。 截至12月1 ...

泰州生物医药产业链撮合平台构建了一个跨区域的产能"调度中心"。企业既可一键发布委托生产需求， 精准说明产品类型、产能规模与认证要求；也可全面展示自身产能优势，从设备参数、工艺标准到国际 认证资质尽数呈现。通过平台智能匹配，产能供需双方能快速"联姻"，让企业产能配置在最合适的地 方，让现有产能得到最有效的释放，实现从"空间"到"时间"的全局优化。该平台动态汇聚和发布国内众 多药品B证企业、科研院所的创新产品信息，覆盖从临床前到审评审批的全阶段。企业可像走进"创新 项目超市"一般，结合自身战略与资源禀赋，提前锁定潜力项目，开展合作研发或成果承接，真正打通 研发与产业化的"任督二脉"，让"金疙瘩"焕发市场光彩。该平台还整合泰州、长三角乃至全国范围内的 CDMO/CMO企业、临床试验机构、药品包装材料企业等关键资源，不论是要找临床合作伙伴，还是寻 求高品质包材供应商，都可以通过平台算法匹配，实现"一键触达"，从而极大地促进本土乃至区域内的 资源内循环与合作创新。 周立 泰州一家药企在获得海外上市申请受理后，却面临一个现实难题：合作方要求必须在美国FDA认证的专 用冻干车间完成生产，可该企业并没有相关生产线，而自建车间 ...

Core Viewpoint - Qianhong Biopharma's stock price has experienced fluctuations, with a year-to-date increase of 44.17%, but a recent decline in the last five trading days by 4.57% [1] Group 1: Company Overview - Qianhong Biopharma, established on April 30, 2003, and listed on February 18, 2011, is located in Changzhou, Jiangsu Province [2] - The company specializes in the research, production, and sales of various pharmaceutical products, including freeze-dried powders, injections, tablets, and raw materials [2] - The main revenue composition is 62.97% from formulations and 36.70% from raw materials [2] Group 2: Financial Performance - For the period from January to September 2025, Qianhong Biopharma achieved a revenue of 1.215 billion yuan, reflecting a year-on-year growth of 0.61%, and a net profit of 383 million yuan, up 23.79% year-on-year [2] - Cumulatively, the company has distributed 1.862 billion yuan in dividends since its A-share listing, with 453 million yuan distributed over the last three years [3] Group 3: Shareholder and Market Activity - As of September 30, 2025, the number of shareholders increased to 73,600, with an average of 12,785 circulating shares per person, a decrease of 1.15% from the previous period [2] - The stock has appeared on the "Dragon and Tiger List" seven times this year, with the most recent instance on August 7, where it recorded a net purchase of 10.2288 million yuan [1]

Company Overview - Harbin Sanlian Pharmaceutical Co., Ltd. is located in Harbin, Heilongjiang Province, established on June 21, 1996, and listed on September 22, 2017. The company specializes in the research, production, and sales of chemical drug formulations [1][2]. Financial Performance - As of November 10, 2023, Harbin Sanlian reported a revenue of 581 million yuan for the period from January to September 2025, a year-on-year decrease of 30.75%. The net profit attributable to the parent company was -209 million yuan, a significant decline of 614.61% [2]. - The company has cumulatively distributed 677 million yuan in dividends since its A-share listing, with 158 million yuan distributed over the past three years [3]. Stock Performance - On November 18, 2023, Harbin Sanlian's stock price increased by 2.34%, reaching 14.89 yuan per share, with a trading volume of 52.42 million yuan and a turnover rate of 2.05%. The total market capitalization stood at 4.711 billion yuan [1]. - Year-to-date, the stock price has risen by 54.30%, with a 2.69% increase over the last five trading days and a 12.12% increase over the last 20 days. However, it has seen a decline of 1.72% over the past 60 days [1]. Shareholder Information - As of November 10, 2023, the number of shareholders for Harbin Sanlian was 39,600, a decrease of 2.98% from the previous period. The average number of circulating shares per person increased by 3.07% to 4,419 shares [2]. Business Segmentation - The main revenue sources for Harbin Sanlian include: large-volume injections (32.00%), lyophilized powder injections (18.39%), solid preparations (17.39%), small-volume injections (14.34%), and other segments such as veterinary drugs (2.55%) and import/export trade (1.82%) [1].

Group 1 - The stock price of Harbin Sanlian Pharmaceutical Co., Ltd. (哈三联) increased by 2.00% on November 14, reaching 15.29 CNY per share, with a trading volume of 1.51 billion CNY and a turnover rate of 5.70%, resulting in a total market capitalization of 48.37 billion CNY [1] - Year-to-date, the stock price has risen by 58.45%, with a 10.00% increase over the last five trading days, a 16.63% increase over the last 20 days, and a 2.55% increase over the last 60 days [2] - The company has appeared on the "龙虎榜" (a stock market leaderboard) nine times this year, with the most recent appearance on June 3 [2] Group 2 - The company's main business revenue composition includes: large-volume infusion (32.00%), lyophilized powder injection (18.39%), solid preparations (17.39%), small-volume injections (14.34%), and others [2] - As of November 10, the number of shareholders is 39,600, a decrease of 2.98% from the previous period, while the average circulating shares per person increased by 3.07% to 4,419 shares [2] - For the period from January to September 2025, the company reported a revenue of 581 million CNY, a year-on-year decrease of 30.75%, and a net profit attributable to shareholders of -209 million CNY, a year-on-year decrease of 614.61% [2] Group 3 - Since its A-share listing, the company has distributed a total of 677 million CNY in dividends, with 158 million CNY distributed over the past three years [3]

Group 1 - The core viewpoint of the news is that Lisheng Pharmaceutical experienced a slight decline in stock price and notable changes in financing activities on November 11, with a net financing outflow of 856.65 million yuan [1] - On November 11, Lisheng Pharmaceutical had a trading volume of 78.11 million yuan, with a financing buy-in amount of 14.07 million yuan and a financing repayment of 22.64 million yuan [1] - As of November 11, the total balance of margin trading for Lisheng Pharmaceutical was 234 million yuan, which accounts for 4.27% of its market capitalization, indicating a high level compared to the past year [1] Group 2 - As of October 20, the number of shareholders for Lisheng Pharmaceutical was 23,900, reflecting a slight increase of 0.13%, while the average circulating shares per person decreased by 0.13% to 10,479 shares [2] - For the period from January to September 2025, Lisheng Pharmaceutical reported an operating income of 1.007 billion yuan, a year-on-year decrease of 1.61%, while the net profit attributable to shareholders increased by 119.05% to 371 million yuan [2] Group 3 - Since its A-share listing, Lisheng Pharmaceutical has distributed a total of 1.261 billion yuan in dividends, with 255 million yuan distributed over the past three years [3]

Group 1 - The announcement states that 10 pharmaceutical companies, including Harbin Pharmaceutical Group, have passed the compliance inspection for Good Manufacturing Practice (GMP) as per the requirements of the Drug Administration Law and the National Medical Products Administration [3][4] - The inspection was conducted on various production lines, including penicillin oral preparations and solid dosage forms, across different facilities in Heilongjiang Province [3][4] - The compliance inspection took place between August and September 2025, with specific dates and production lines detailed for each company [3][4] Group 2 - The companies inspected include Harbin Guokang Pharmaceutical Co., Harbin Sanlian Pharmaceutical Co., and Heilongjiang Boyu Pharmaceutical Co., among others, indicating a broad scope of compliance across the local pharmaceutical industry [3][4] - The inspection results are part of ongoing efforts to ensure quality standards in pharmaceutical manufacturing, which is critical for maintaining public health and safety [3][4] - The announcement serves as a public record of compliance, which may enhance the reputation and marketability of the companies involved [3][4]

Group 1 - The core viewpoint of the news is that Tianjin Lifeng Pharmaceutical Co., Ltd. has experienced fluctuations in its stock price and trading volume, with a notable decline in recent days despite a year-to-date increase in stock price [1][2] - As of November 4, the stock price of Lifeng Pharmaceutical was 21.31 yuan per share, with a market capitalization of 5.49 billion yuan and a trading volume of 59.43 million yuan [1] - The company has seen a year-to-date stock price increase of 23.24%, but has declined by 2.38% in the last five trading days, 6.70% in the last twenty days, and 12.91% in the last sixty days [1] Group 2 - Lifeng Pharmaceutical's main business includes the production and sales of various pharmaceutical products, with the revenue composition being 59.92% from tablets, 15.69% from injections, 8.80% from pills, 8.75% from capsules, and 4.68% from other products [2] - The company has a total of 23,900 shareholders as of October 20, with an average of 10,479 circulating shares per shareholder [2] - For the period from January to September 2025, Lifeng Pharmaceutical reported a revenue of 1.007 billion yuan, a year-on-year decrease of 1.61%, while the net profit attributable to the parent company was 371 million yuan, reflecting a year-on-year increase of 119.05% [2] Group 3 - Since its A-share listing, Lifeng Pharmaceutical has distributed a total of 1.261 billion yuan in dividends, with 255 million yuan distributed over the past three years [3]

Group 1 - The core viewpoint of the news is that Harbin Sanlian Pharmaceutical Co., Ltd. has shown a significant stock price increase and trading activity, indicating potential investor interest and market performance [1][2]. - As of October 15, Harbin Sanlian's stock price rose by 2.03% to 13.54 CNY per share, with a total market capitalization of 4.283 billion CNY [1]. - The company has experienced a 40.31% increase in stock price year-to-date, with a recent 5-day increase of 5.95% [1]. Group 2 - Harbin Sanlian's main business revenue composition includes: large-volume infusion (32.00%), lyophilized powder injection (18.39%), solid preparations (17.39%), and small-volume injections (14.34%) [1]. - The company operates in the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and preparations, with involvement in various concept sectors such as cosmetics and hypertension treatment [2]. - As of September 19, the number of shareholders decreased by 3.78% to 37,700, while the average circulating shares per person increased by 3.92% to 4,595 shares [2]. Group 3 - Harbin Sanlian has distributed a total of 677 million CNY in dividends since its A-share listing, with 158 million CNY distributed over the past three years [3]. - For the first half of 2025, the company reported a revenue of 413 million CNY, a year-on-year decrease of 21.08%, and a net profit attributable to shareholders of -92.39 million CNY, a decrease of 451.68% [2].